Medical articles today

/* 728x15, */

What Is Clostridium Difficile C. Difficile ?

Clostridium difficile, also known as C. difficile, or C. diff, is a bacterium which infects and can make humans ill, as well as other animals. Symptoms can range from diarrhea to serious and potentially fatal inflammation of the colon. Elderly hospital patients, as well as those in long-term care facilities are most commonly affected by C. difficile - especially after or during the use of antibiotic drugs. C. difficile infection is gradually becoming more common, symptoms more severe and harder to treat. In North America, Europe, Australasia and many other parts of the world a significant number of people become ill from C. difficile - not only hospitalized patients taking antibiotics, but also otherwise healthy individuals.

First Effective Medical Therapy For Rare Stomach Disorder Reported By Vanderbilt Scientists

A drug used to treat colorectal cancer also can reverse a rare stomach disorder and should be considered first-line therapy for the disease, researchers at Vanderbilt University Medical Center report this week. Mà nà trier's disease causes thickening of the stomach lining, severe abdominal pain, nausea and vomiting, as well as anemia and swelling in the feet and ankles due to protein loss. Patients are at increased risk for gastric cancer. Previously, the only effective treatment was gastrectomy - surgical removal of the stomach. The targeted cancer drug cetuximab, brand name Erbitux, relieved symptoms of severe Mà nà trier's disease in seven patients who completed a one-month course of treatment.

/* 468x60, */

News From The November Issue Of GIE: Gastrointestinal Endoscopy

"Screening for Barrett's esophagus in asymptomatic women" Barrett's esophagus is a condition where the lining of the esophagus changes due to chronic inflammation, generally from gastroesophageal reflux disease (GERD). Barrett's esophagus is important to recognize as it may increase the risk of developing esophageal cancer. It has been detected in approximately 10 percent of patients with GERD, but previous studies have demonstrated a similar prevalence of Barrett's esophagus in asymptomatic adults. The majority of patients found to have asymptomatic Barrett's esophagus in previous studies were male and white. Whether asymptomatic Barrett's esophagus occurs in women has not been well studied.

Ception Therapeutics And Cephalon Provide Initial Results Of A Phase IIb III Study Of CINQUIL In Pediatric Eosinophilic Esophagitis

Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. (Nasdaq: CEPH) announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms. Analyses of the data indicated that patients treated with CINQUIL showed a statistically significant reduction in esophageal eosinophil levels versus placebo. In the second co-primary endpoint, patients treated with CINQUIL showed an improvement in their clinical symptoms;

Boston Scientific Announces FDA Clearance And CE Mark For WallFlex R Fully Covered Esophageal Stent

Boston Scientific Corporation (NYSE: BSX) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex® Fully Covered Esophageal Stent for the treatment of malignant esophageal strictures (obstructions) caused by tumors in patients with resectable or non-resectable esophageal cancer. The WallFlex® Partially Covered Esophageal Stent was cleared by the FDA and received CE Mark in 2008. Both stents -- along with the complete WallFlex Stent family of self-expanding metal stents (SEMS) -- will be available for hands-on demonstration at the GASTRO 2009 conference, which is being held November 21-25 in London.

/* 468x60, */

Interim Data From A Clinical Trial Evaluating GI Dynamics' EndoBarrier trade; Gastrointestinal Liner In Patients With Type 2 Diabetes

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, announced that interim data from its ongoing clinical study of the EndoBarrier™ Gastrointestinal Liner in obese patients with type 2 diabetes will be presented by Eduardo G. Moura, M.D., Ph.D., director of endoscopy, digestive surgery department, Hospital das Clinicas, University of Sao Paulo, on Monday, November 23, 2009 at GASTRO 2009 organized by the United European Gastroenterology Federation (UEGF), World Gastroenterology Organisation (WGO), World Organisation of Digestive Endoscopy (OMED) and British Society of Gastroenterology (BSG), in London.

Fast: [10] [20] [30] [40] [50] [60]
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy